Антагонисты минералокортикоидных рецепторов: сомнительное прошлое и перспективное настоящее

Обложка
  • Авторы: Напалков Д.А.1
  • Учреждения:
    1. ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
  • Выпуск: Том 17, № 5 (2015)
  • Страницы: 63-67
  • Раздел: Статьи
  • URL: https://journals.rcsi.science/2075-1753/article/view/94299
  • ID: 94299

Цитировать

Полный текст

Аннотация

В обзорной статье анализируются имеющиеся в литературе данные по применению антагонистов минералокортикоидных рецепторов, представленных на российском рынке, - спиронолактона и эплеренона - при разных нозологиях, включая первичный гиперальдостеронизм, артериальную гипертензию, сердечную недостаточность, инфаркт миокарда, хроническую болезнь почек. Особый акцент сделан на вопросах переносимости и безопасности. Предпринята попытка дифференциального подхода к выбору спиронолактона и эплеренона в разных подгруппах больных.

Об авторах

Дмитрий Александрович Напалков

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

Email: dminap@mail.ru
д-р мед. наук, проф. каф. факультетской терапии №1 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Список литературы

  1. Tamargo H, Solini A, Ruilope L.M. Comparison of agents that affect aldosterone action. Semin Nephrol 2014; 34: 285-306.
  2. Messaoudi S, Jaisser F. Aldosterone and the mineralocorticoid receptor. Eur Heart J Suppl 2011; 13: B4-В9.
  3. Brown N.J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013; 9: 459-69.
  4. Williams J.S, Williams G.H. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88: 2364-72.
  5. Messaoudi S, Azibani F, Delcayre C et al. Aldosterone, mineralocorticoid receptor, and heart failure. Moll Cell Endocrinol 2012; 350: 266-72.
  6. Bledsoe R.K, Madauss K.P, Holt J.A et al. A ligand - mediated hydrogen bond network required for the activation of the mineralocorticoid receptors. J Biol Chem 2005; 280 (31): 283-93.
  7. Fagart J, Huyet J, Pinon G.M et al. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 2005; 12: 554-5.
  8. Hultman M.L, Krasnoperova N.V, Li S et al. The ligand - dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 2005; 19: 1460-73.
  9. Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-9.
  10. Garthwaite S.M, Mc Mahon E.G. The evolution of aldosterone antagonists. Moll Cell Endocrinol 2004; 217: 27-31.
  11. Rossi G.P. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011; 7: 485-95.
  12. Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone vs. eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9: 509-15.
  13. Partharasarathy H.K, Menard J, White W.B et al. A double - blind randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-90.
  14. Newton-Cheh C, Guo S.Y, Gona P et al. Clinical and genetic correlates of aldosterone of aldosterone - to - renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846-56.
  15. Meneton P, Galan P, Bertrais S et al. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle - aged Caucasian populations. J Hum Hypertens 2008; 22: 550-8.
  16. Nishizaka M.K, Zaman M.A, Calhoun D.A. Efficacy of low - dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-30.
  17. Chapman N, Dobson J, Wilson S et al. Anglo-Scandinavian Outcomes Trial Investigators. Effects of spironolacton on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-45.
  18. Weinberger M.H, White W.B, Ruilope L.M et al. Effects of eplerenone versus losartan in patients with low - renin hypertension. Am Heart J 2005; 150: 426-33.
  19. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricle hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-8.
  20. Calhoun D.A, White W.B. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2: 462-8.
  21. Zannad F, Gattis Stough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence in clinical practice. Eur Heart J 2012; 33: 2782-95.
  22. Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study Group. Circulation 1990; 82: 1730-6.
  23. Yancy C.W, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Card 2013; 62 (16): e147-e239.
  24. Milliez P, Deangelis N, Rucker-Martin C et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005; 26: 2193-9.
  25. Beygui F, Labbe J.P, Cayla G et al. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life - threating ventricular arrhythmia. Int J Cadiol 2013; 167: 73-9.
  26. Swedberg K, Zannad F, Mc Murray J.J et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Elerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598-603.
  27. Mc Manus F, Mc Innes G.T, Connell J.M. Drug insight: eplerenone, a mineralocorticoid receptor antagonist. Nat Clin Pract Endocrinol Metab 2008; 4: 44-52.
  28. Epstein M, Williams G.H, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-51.
  29. Navaneethan S.D, Nigwekar S.U, Sehgal A.R et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta - analysis. Clin J Am Kidney Dis 2009; 4: 542-51.
  30. Gulmez S.E, Lassen A.T, Aalykke C et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population - based case - control study. Br J Clin Pharmacol 2008; 66: 294-99.
  31. Jeunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-5.
  32. Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
  33. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
  34. Zannad F, Mc Murray J.J, Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
  35. Pitt B, Bakris G, Ruilope L.M et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-50.
  36. Ezekowitz J.A, Mc Alister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-77.
  37. Eschalier R, Mc Murray J.J, Swedberg K et al. EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalizations And Survival Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-93.

© ООО "Консилиум Медикум", 2015

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах